Business
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.
About this update from Azitra Inc
[{"type":"text","content":"MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.","length":522,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Expanding our clinical footprint to include MD Anderson Cancer Center, a world-renowned institution, is a significant milestone for the ATR-04 program," said Francisco Salva, CEO of Azitra. "As a leading cancer site that treats thousands of patients a year, oncologists at MD Anderson understand the impact of EGFRi-associated rash, which impacts up to 80% of patients receiving EGFRi therapies. As this major side effect frequently leads to treatment interruptions or discontinuations, the field is in need of innovative solutions like ATR-04, a topically applied product with the potential to help patients stay on their primary cancer treatments. We're glad to be working with the committed staff at MD Anderson, our sixth clinical site, as we aim to accelerate the development of our ATR-04 program."","length":829,"tagName":"p"},{"type":"text","content":"The multicenter, randomized, double-bli...